MedTrace Logo

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

NCT02962895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2025-01-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Conditions

  • Primary Sjogren Syndrome

Interventions

BIOLOGICAL

VAY736

VAY736

OTHER

Placebo

Placebo control

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-27
Primary Completion
2020-06-30
Completion
2021-09-23
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • Chile
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Russia
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02962895 on ClinicalTrials.gov